10:55 AM EDT, 06/26/2024 (MT Newswires) -- Moderna ( MRNA ) said Wednesday that its mRESVIA respiratory syncytial virus or RSV vaccine demonstrated about a 50% efficacy after 18 months based on data from a pivotal phase 2/3 trial.

The trial enrolled adult patients of at least 60 years old across 22 countries, according to the company.

Moderna ( MRNA ) said mRESVIA was approved by the US Food and Drug Administration in May as active immunization to prevent lower respiratory tract disease caused by RSV in adult patients 60 years old and above.

Shares of Moderna ( MRNA ) were down more than 5% in recent trading.

Price: 130.58, Change: -7.02, Percent Change: -5.10